121 Seaport Square Update 09/12/17

121 Seaport now 100%-leased with Alexion Pharmaceuticals’ lease of 150,000 square feet


Alexion Pharmaceuticals, currently based in New Haven, CT, will open a new 150,000-square-foot headquarters at 121 Seaport, bringing the state-of-the-art elliptical office tower to 100% occupancy. Last week, it was announced that Internet of Things (IoT) technology provider PTC has leased 250,000 square feet at 121 Seaport; the building features 400,000 square feet of Class A office space. Alexion, a global biopharmaceutical company that develops and delivers life-changing therapies for patients with rare diseases, will occupy floors three through eight of 121 Seaport and open its’ new headquarters in June 2018.


Newmark Knight Frank represented 121 Seaport developer Skanska in both Alexion and PTC’s leases; Cushman & Wakefield represented Alexion, and Cresa represented PTC. “121 Seaport now being 100 percent leased demonstrates the Seaport’s arrival as one of Boston’s most sought-after submarkets and business destinations,” said Charley Leatherbee, head of Skanska’s Commercial Development operations in Boston, in a prepared statement. “We delivered a building based on flexibility, innovation, sustainability and efficiency. We are honored that a pioneering company such as Alexion selected our building. Alexion and PTC are moving their respective industries forward in a building that pushes the boundaries of traditional design.” 121 Seaport will open in the first quarter of 2018, and also features 50,000 square feet of prime retail across its’ first two floors.

View 121 Seaport Square >>

Search BLDUP

Search BLDUP for news, projects, and companies to find the information that pushes your business forward.

Related News